BRCA1 Mutation Clinical Trial
Official title:
Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study
The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of cells in the breast, but if it mutates may lead to breast cancer) mutations undergoing a planned prophylactic mastectomy (having one or both breasts removed).
This is a single arm, prospective, observational trial enrolling up to 10 patients within Indiana University Simon Comprehensive Cancer Center. Eligible women will be consented to undergo breast biopsy 2-6 days prior to prophylactic mastectomy and take one dose of mifepristone 2 days prior to prophylactic mastectomy. If the initial biopsy is obtained on Day -2, the mifepristone should be taken AFTER the biopsy. Tissue from the ipsilateral breast will be taken at the time of mastectomy. Primary Objective To determine the impact of a single 200 mg dose of mifepristone on gene expression and metabolomic alterations in breast tissue of women with BRCA1 mutations who are planning prophylactic mastectomy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT04499534 -
BRCA1/2 Flu Vaccine
|
||
Recruiting |
NCT05537844 -
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
|
||
Active, not recruiting |
NCT03685331 -
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
|
Phase 1 | |
Recruiting |
NCT05097274 -
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a BRCA Gene Mutation.
|
||
Completed |
NCT03428399 -
Depression and Body Image Distress Following Mastectomy With Reconstruction
|
||
Completed |
NCT02957981 -
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
|
N/A | |
Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04651920 -
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
|
||
Completed |
NCT02974842 -
Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance
|
||
Active, not recruiting |
NCT03351803 -
BRCA Founder OutReach (BFOR) Study
|
||
Suspended |
NCT04151368 -
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
|
N/A | |
Active, not recruiting |
NCT04273542 -
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening
|
N/A | |
Recruiting |
NCT05694715 -
Combination Therapy in Cancers With Mutations in DNA Repair Genes
|
Phase 1 | |
Recruiting |
NCT06395519 -
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
|
Phase 1 | |
Recruiting |
NCT05410951 -
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
|
||
Completed |
NCT04108117 -
Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction
|